以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。
数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15
GRAL
4 atoms · 跨 2 天 · 首见 2026-06-05 · 最近 2026-06-18
三色: 🟦 fact 0 · 🟥 take 4 · stance ▲0/▼2/◆2
来源: 群 1 · X 3
时态: fresh:2 · stale:2
标签: 好观点:2 · 好数字:1 · 好思考:1
叙事 (narrative) (1)
- 2026-06-05 · path to profitability hinges on uncertain FDA approval and CMS coverage for Galleri test
Analyst sees GRAL's path to profitability hinging on uncertain FDA approval and CMS coverage for its Galleri multi-cancer early detection test.
tags: 好思考 · → daily
反驳 (refute) (1)
- 2026-06-18 ◌ · 试验数据差，不建议触碰
GRAL 试验数据差，不碰
tags: 好观点 · → daily
立场 (position) (2)
展开 2 条老旧 / 已过期
- 2026-06-05
[老旧] · Goldman Sachs coverage initiation rating
$GRAL | Goldman Sachs 𝐢𝐧𝐢𝐭𝐢𝐚𝐭𝐞𝐬 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞 on 𝐆𝐑𝐀𝐈𝐋 with a 𝐍𝐞𝐮𝐭𝐫𝐚𝐥 rating
tags: 好观点 · → daily
value: direction=Neutral
- 2026-06-05
[老旧] · Goldman Sachs price target
𝐩𝐫𝐢𝐜𝐞 𝐭𝐚𝐫𝐠𝐞𝐭 𝐨𝐟 $𝟔𝟎
tags: 好数字 · → daily
value: qty=$60 · date=initiation
时间轴 (近 20)
- 2026-06-18 ·
refute · 试验数据差，不建议触碰 · → daily
- 2026-06-05 ·
position · Goldman Sachs coverage initiation rating · → daily
- 2026-06-05 ·
position · Goldman Sachs price target · → daily
- 2026-06-05 ·
narrative · path to profitability hinges on uncertain FDA approval and C · → daily
← 实体目录 · 系统日志